Skip to main content
Year archive

NEURIZON THERAPEUTICS LIMITED — 2023 filings

All 105 regulatory filings released by NEURIZON THERAPEUTICS LIMITED (NUZ) in 2023, sourced directly from the official regulator.

105 Filings
2023 Period
2023 filings (105)
Filing Released Lang
FightMND Invites PharmAust to Apply for Phase 2/3 Funding 2 pages 168.9KB
Regulatory Filings
2023-12-21 English
Application for quotation of securities - PAA 7 pages 30.5KB
Capital/Financing Update
2023-12-21 English
Cleansing Notice 1 page 223.8KB
Capital/Financing Update
2023-12-21 English
Application for quotation of securities - PAA 6 pages 27.9KB
Share Issue/Capital Change
2023-12-20 English
Application for quotation of securities - PAA 6 pages 28.5KB
Capital/Financing Update
2023-12-20 English
PharmAust Receives R&D Tax Incentive Refund 2 pages 152.2KB
Regulatory Filings
2023-12-19 English
PAAOA Top 20 & Distribution Report 3 pages 114.7KB
Major Shareholding Notification
2023-12-18 English
Update - Proposed issue of securities - PAA 7 pages 33.7KB
Capital/Financing Update
2023-12-17 English
Application for quotation of securities - PAA 7 pages 30.4KB
Share Issue/Capital Change
2023-12-17 English
Cleansing Notice 1 page 223.4KB
Share Issue/Capital Change
2023-12-17 English
PharmAust Launches Interactive Investor Hub 1 page
Regulatory Filings
2023-12-17 English
Appendix 2A 20 pages 529.0KB
Capital/Financing Update
2023-12-17 English
Appendix 3Y x 4 9 pages 413.8KB
Director's Dealing
2023-12-17 English
93% take up in Options Offer 1 page 164.7KB
Capital/Financing Update
2023-12-14 English
Update - Proposed issue of securities - PAA 6 pages 30.4KB
Capital/Financing Update
2023-12-13 English
PharmAust Raises $3.5 Million at a Premium 2 pages 185.3KB
Capital/Financing Update
2023-12-12 English
Proposed issue of securities - PAA 7 pages 33.6KB
Capital/Financing Update
2023-12-12 English
Trading Halt 2 pages 572.0KB
Capital/Financing Update
2023-12-10 English
New Hires & Attendance at International MND Symposium 2 pages 225.1KB
Board/Management Information
2023-12-05 English
PAA completes Phase 1 and files for Orphan Drug Designation 2 pages 199.4KB
Capital/Financing Update
2023-11-30 English
Prospectus & Target Market Determination 34 pages 598.1KB
Capital/Financing Update
2023-11-20 English
Results of Annual General Meeting 2 pages 286.2KB
Declaration of Voting Results & Voting Rights Announcements
2023-11-19 English
Appendix 3Y x 4 10 pages 360.7KB
Director's Dealing
2023-11-05 English
PharmAust to present at Emerging ASX Gems Conference 1
Regulatory Filings
2023-11-01 English
Appendix 4C and Quarterly Update 22 pages 3.6MB
Interim / Quarterly Report Q1 2024
2023-10-29 English
Application for quotation of securities - PAA 6 pages 27.8KB
Share Issue/Capital Change
2023-10-26 English
Notice of Annual General Meeting & Proxy Form 26 pages 653.8KB
AGM Information
2023-10-18 English
Options Offer to Existing Listed Option Holders 2 pages 281.3KB
Capital/Financing Update
2023-10-17 English
Proposed issue of securities - PAA 6 pages 30.5KB
Capital/Financing Update
2023-10-17 English
Final MND Patient in Cohort 4 Successfully Completes Dosing 3 pages 244.8KB
Regulatory Filings
2023-10-12 English
Canine Oncology Data Supports Progression to Registration 11 pages 1.3MB
Capital/Financing Update
2023-10-08 English
Trading Halt 2 pages 547.7KB
Regulatory Filings
2023-10-05 English
Clarification to notification of expiry of quoted options 1
Regulatory Filings
2023-10-01 English
Notification of expiry of quoted options 1 page 169
Capital/Financing Update
2023-09-28 English
Change of registry address notification 1 page 161.
Regulatory Filings
2023-09-14 English
Notification regarding unquoted securities - PAA 8 pages 35.7KB
Share Issue/Capital Change
2023-09-07 English
Application for quotation of securities - PAA 6 pages 27.5KB
Capital/Financing Update
2023-09-03 English
Cleansing Notice 1 page 223.3KB
Share Issue/Capital Change
2023-09-03 English
Appendix 4E & Full Year Statutory Accounts 57 pages 2.2MB
Annual Report FY 2023
2023-08-30 English
Appendix 4G & Corporate Governance Statement 25 pages 778.1KB
Regulatory Filings
2023-08-30 English
Chief Executive Officer Appointment 3 pages 234.2KB
Board/Management Information
2023-08-27 English
Release of Restricted Securities from Escrow 1 page
Capital/Financing Update
2023-08-24 English
Additional Phase 1 data suggest MPL may inhibit MND 3 pages 375.3KB
Regulatory Filings
2023-08-21 English
Trading Halt 2 pages 574.7KB
Regulatory Filings
2023-08-16 English
Cohort 3 Pharmacokinetics in MND Patients Completed 3 pages 325.8KB
Regulatory Filings
2023-08-08 English
Epichem enters voluntary liquidation 1 page 159.6KB
Regulatory Filings
2023-07-31 English
Appendix 4C and Quarterly Update 15 pages 1.8MB
Interim / Quarterly Report Q4 2023
2023-07-30 English
MND Trial Successfully Completes 3rd Patient Cohort 2 pages 198.9KB
Regulatory Filings
2023-07-27 English
Canine Trial Update 11 pages 1.4MB
Regulatory Filings
2023-07-12 English
Results show MPL suppresses biomarkers associated with MND 2 pages 265.9KB
Regulatory Filings
2023-07-10 English
Trading Halt 2 pages 599.0KB
Regulatory Filings
2023-07-09 English
Application for quotation of securities - PAA 6 pages 27.8KB
Share Issue/Capital Change
2023-07-06 English
Notification regarding unquoted securities - PAA 7 pages 29.0KB
Share Issue/Capital Change
2023-07-06 English
Notification of cessation of securities - PAA 4 pages 23.8KB
Regulatory Filings
2023-07-06 English
s708A(5)(e) notice 1 page 216.6KB
Capital/Financing Update
2023-07-06 English
Change of Director's Interest Notice x 3 7 pages 305.4KB
Director's Dealing
2023-07-06 English
Louie the Beagle surpasses one year on MPL 4 pages 465.9KB
Regulatory Filings
2023-07-05 English
MND Biomarkers and Pharmacodynamics Results 3 pages 363.1KB
Regulatory Filings
2023-07-03 English
General Meeting - Chairman Script 6 pages 296.2KB
AGM Information
2023-06-29 English
Trading Halt 2 pages 231.2KB
Regulatory Filings
2023-06-29 English
Results of General Meeting 2 pages 363.1KB
Declaration of Voting Results & Voting Rights Announcements
2023-06-29 English
Motor Neurone Disease Phase 1/2 Clinical Trial Update 2 pages 226.1KB
Regulatory Filings
2023-06-26 English
Commencement of Cohort 3 in Phase 1/2 MND Trial 2 pages 218.2KB
Capital/Financing Update
2023-06-08 English
PharmAust MND Trial Interim Analysis PK Outcomes 3 pages 388.5KB
Interim / Quarterly Report FY 2023
2023-06-06 English
Trading Halt 2 pages 602.1KB
Regulatory Filings
2023-06-04 English
Notice of General Meeting/Proxy Form 21 pages 635.1KB
Proxy Solicitation & Information Statement
2023-05-25 English
Motor Neurone Disease Clinical Trial Update 2 pages 221.7KB
Regulatory Filings
2023-05-21 English
Progress update on Phase 1/2 MND interim analysis 2 pages 275.6KB
Capital/Financing Update
2023-05-15 English
Securities issued under LR7.1 & LR7.1A 1 page 208.6
Capital/Financing Update
2023-05-15 English
Application for quotation of securities - PAA 6 pages 27.5KB
Share Issue/Capital Change
2023-05-10 English
Notification regarding unquoted securities - PAA 7 pages 30.6KB
Capital/Financing Update
2023-05-10 English
Notification regarding unquoted securities - PAA 7 pages 30.8KB
Share Issue/Capital Change
2023-05-10 English
Section 708(5) Notice 1 page 216.3KB
Share Issue/Capital Change
2023-05-10 English
Appendix 3Y 2 pages 211.4KB
Director's Dealing
2023-05-10 English
Terms & Conditions of Unlisted Options 1 page 103.1
Capital/Financing Update
2023-05-10 English
Notification regarding unquoted securities - PAA 7 pages 31.0KB
Share Issue/Capital Change
2023-05-10 English
Cancel - Notification regarding unquoted securities - PAA 7 pages 30.5KB
Share Issue/Capital Change
2023-05-10 English
Application for quotation of securities - PAA 7 pages 30.4KB
Capital/Financing Update
2023-05-10 English
Independent tests show MPL retains long-term shelf-life 2 pages 291.0KB
Capital/Financing Update
2023-05-09 English
MPL has anti-cancer effects across multiple cancer types 3 pages 684.1KB
Regulatory Filings
2023-05-08 English
PharmAust Raises $2.5m via Placement 2 pages 218.7KB
Capital/Financing Update
2023-05-02 English
Proposed issue of securities - PAA 6 pages 31.1KB
Capital/Financing Update
2023-05-02 English
MND Trial Successfully Completes Second Patient Cohort 3 pages 238.3KB
Capital/Financing Update
2023-04-27 English
Trading Halt 2 pages 592.7KB
Capital/Financing Update
2023-04-27 English
Appendix 4C and Quarterly Update 15 pages 1.3MB
Interim / Quarterly Report Q3 2023
2023-04-27 English
Canine Trial Update 10 pages 1.5MB
Regulatory Filings
2023-04-20 English
Arrival of additional MPL tablets 2 pages 233.9KB
Capital/Financing Update
2023-04-16 English
PharmAust launches international CEO search 1 page
Board/Management Information
2023-04-12 English
MND Trial Completes Enrolment of Cohort 2 2 pages 215.3KB
Capital/Financing Update
2023-03-29 English
Stable Patient in MND trial reaches 6-months on MPL 2 pages 206.3KB
Regulatory Filings
2023-03-27 English
PharmAust Investor Webinar Presentation 26 pages 3.8MB
Investor Presentation
2023-03-15 English
AOG Energy Conference Presentation 18 pages 2.9MB
Regulatory Filings
2023-03-14 English
Investor Webinar 1 page 200.2KB
Investor Presentation
2023-03-13 English
Change of Director's Interest Notice 2 pages 193.1KB
Director's Dealing
2023-03-12 English
Correction to Appendix 3Y 2 pages 193.1KB
Director's Dealing
2023-03-12 English
Canine Cancer Trial Update 4 pages 305.5KB
Regulatory Filings
2023-03-06 English
Interim analysis recommended in MND trial 2 pages 260.7KB
Regulatory Filings
2023-03-01 English
European Patent relating to MPL Combinations in Cancer 2 pages 208.0KB
Regulatory Filings
2023-02-27 English
Appendix 4D & Half Year Report 19 pages 477.1KB
Interim / Quarterly Report H1 2023
2023-02-26 English
First Patient of Cohort 2 Dosed in MND Trial 3 pages 271.9KB
Regulatory Filings
2023-02-19 English
PharmAust canine trial update 18 pages 2.5MB
Management Reports
2023-02-09 English
Appendix 4C and Quarterly Update 19 pages 2.9MB
Interim / Quarterly Report Q2 2023
2023-01-29 English
PharmAust Progresses to Elevated Doses in MND Patients 2 pages 207.1KB
Regulatory Filings
2023-01-19 English
Change of Director's Interest Notice 2 pages 193.3KB
Director's Dealing
2023-01-09 English
MND Trial Successfully Completes First Patient Cohort 2 pages 255.1KB
Regulatory Filings
2023-01-05 English